Aeterna submits macimorelin acetate for FDA review

11/6/2013 | Pharmaceutical Business Review Online

Aeterna Zentaris filed an application with the FDA for approval to market its experimental drug macimorelin acetate, or AEZS-130, for evaluation of adult growth hormone deficiency. If approved, the drug would be the first oral product cleared for AGHD assessment. The drug is also in a midstage trial for cancer-induced cachexia.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC